Toward molecular imaging-driven drug development in oncology

Cancer Discovery

Volumn 1, Issue 1, 2011, Pages 25-28

  de Vries, Elisabeth G E ^a   Munnink, Thijs H Oude ^a   van Vugt, Marcel A T M ^a   Nagengast, Wouter B ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; ANDROGEN RECEPTOR; BEVACIZUMAB; BICALUTAMIDE; ENZALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORESCEIN ISOTHIOCYANATE; FLUORODEOXYGLUCOSE F 18; FLUTAMIDE; FOLATE RECEPTOR 1; HEAT SHOCK PROTEIN 90 INHIBITOR; INDIUM 111; RANIBIZUMAB; SUNITINIB; TAMOXIFEN; TRACER; TRASTUZUMAB; TUMOR MARKER; VASCULOTROPIN;

ARTICLE; AUTOFLUORESCENCE IMAGING; BLOOD SAMPLING; BREAST CANCER; CANCER MORTALITY; CELL HETEROGENEITY; CONFOCAL LASER MICROSCOPY; DRUG DEVELOPMENT; FLUORESCENCE IMAGING; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIOACTIVITY; RECEPTOR AFFINITY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR BIOPSY;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84861232301     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8274.CD-11-0051     Document Type: Article

References (16)

1. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million? Health Aff 2006;25:420-8.
2. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010;467:543-9.
3. van Bruggen N, Fine BM, Rudin M. Molecular and functional imaging in drug development. In: R. Weissleder, BD Ross, A Rehemtulla, SS Gambhir, editors. Molecular imaging, principles and practice. Shelton, CT: People's Medical Publishing House-USA; 2010. p. 1161-78.
4. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999;26:51-6.
5. Dehdashti F, Picus J, Michalski JM, Dence CS, Siegel BA, Katzenellenbogen JA, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005;32:344-50.
6. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46.
7. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.
8. Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006;24:2276-82.
9. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010;87:586-92.
10. Oude Munnink TH, Dijkers EC, Netters SJ, Lub-de Hooge MN, Brouwers AH, Haasjes JG, et al. Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load. J Clin Oncol 2010;28:e355-6.
11. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004;22:701-6.
12. Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, Hollema H, et al. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 2010;51:761-7.
13. Nagengast WB, Lub-de Hooge MN, Oosting SF, den Dunnen WF, Warnders FJ, Brouwers AH, et al. VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res 2011;71:143-53.
14. Hsiung PL, Hardy J, Friedland S, Soetikno R, Du CB, Wu AP, et al. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat Med 2008;14:454-8.
15. Marshall MV, Draney D, Sevick-Muraca EM, Olive DM. Single-dose intravenous toxicity study of IRDye 800CW in Sprague-Dawley rats. Mol Imaging Biol 2010;12:583-94.
16. Sampath L, Kwon S, Ke S, Wang W, Schiff R, Mawad ME, et al. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med 2007;48:1501-10.